Arialys Therapeutics

LA JOLLA, CA · Founded 2021 · Biotech · Private

Small molecule therapeutics targeting neuroinflammation and psychiatric disorders

Claim this profile

Follows are private to you and power your alerts

Updated · arialystx.com

Sector
Biotech
Headquarters
LA JOLLA, CA
Founded
2021
Latest Form D
$14.8M, Jul 2025
Total capital
$29.1M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$29.1M
2 Form D · last Jul 2025
16 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
11 pending · first 2025
Rank in peer group#397 of 1449

Capital timeline

2022202320242025FEDERAL ↑EQUITY ↓Cumulative $29.1M1st Form D$14.3M2nd Form D$14.8M
2022202320242025FEDERAL ↑EQUITY ↓Cumulative $29.1M1st Form D$14.3M2nd Form D$14.8M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$14.8M
  • Private capital raisedForm D · SEC · 1st filing$14.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Ashish Xavier, Ph.D.DirectorNamed in SEC Form D filings
  • Brian Slingsby, M.D., Ph.D., M.P.H.DirectorNamed in SEC Form D filings
  • Ed HurwitzDirectorNamed in SEC Form D filings
  • Jay Lichter, Ph.D.DirectorNamed in SEC Form D filings
  • Peter Flynn, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
  • Tighe ReardonExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 13
Show all 13 patent records
  • Anti-human NR1 Antibody DerivativeJun 9, 2026 · US 12,649,786Granted
  • Methods And Systems For Identifying Or Treating Central Nervous Systems DiseaseAug 21, 2025 · Application 19035338Pending
  • Anti-human NR1 Antibody DerivativeJun 17, 2025 · US 12,331,113Granted
  • Detection Of Autoantibodies Against NR1Application 63701162Pending
  • Methods Of Treating Anti- Nmdar Antibody Related DisordersApplication 63673454Pending
  • Detection Of Autoantibodies Against NR1Application PCTUS2024022024Pending
  • Methods And Systems For Identifying Or Treating Central Nervous Systems DiseaseApplication PCTUS2023071138Pending
  • Detection Of Autoantibodies Against NR1Application 63493217Pending
  • Methods And Systems For Identifying Or Treating Central Nervous Systems DiseaseApplication 63369923Pending
  • Detection Of Autoantibodies Against NR1Application PCTUS2025048528Pending
  • Detection Of Autoantibodies Against NR1Application 19168281Pending
  • Methods Of Treating Anti-nmdar Antibody Related DisordersApplication PCTUS2025038125Pending
  • Detection Of Autoantibodies Against NR1Application 63729630Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .